Sunshine Biopharma Files 2024 Annual Report
Ticker: SBFMW · Form: 10-K · Filed: Apr 1, 2025 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma Inc. (SBFMW) |
| Form Type | 10-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Sunshine Biopharma dropped its 2024 10-K. All systems go on financials.
AI Summary
Sunshine Biopharma Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, operating in pharmaceutical preparations, is headquartered in Fort Lauderdale, Florida. The filing covers financial data and business operations for the period, including details on common stock and preferred stock.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Sunshine Biopharma's financial health and operational status for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Sunshine Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2023-12-31 — Prior Year End (Comparison point for financial data)
Key Players & Entities
- Sunshine Biopharma Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- Fort Lauderdale, Florida (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is Sunshine Biopharma's primary business activity?
Sunshine Biopharma Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
When did Sunshine Biopharma file its 10-K for the fiscal year 2024?
The 10-K filing for the fiscal year ending December 31, 2024, was filed on April 1, 2025.
Where is Sunshine Biopharma Inc. located?
The company's business and mailing address is 333 Las Olas Way, Suite CU4 433, Fort Lauderdale, FL 33301.
What are some of the financial components mentioned in the filing?
The filing references financial components such as Common Stock, Warrant, Series B Preferred Stock, Additional Paid In Capital, Preferred Stock, Comprehensive Income, and Retained Earnings for the fiscal years 2023 and 2024.
What was the SEC file number for this 10-K filing?
The SEC file number for this 10-K filing is 001-41282.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 1, 2025 regarding Sunshine Biopharma Inc. (SBFMW).